Cytokinetics Inc. (CYTK)
Last updated: 2026-10-22 05:11:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Summary
Cytokinetics Inc. (CYTK) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $62.90, with a market capitalization of $8.71B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $54.30 to $88.31. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$8.71B | |
$64.30 | |
$110.25 | |
$3.05 | |
$63.95 | |
801.67K | |
1.97M | |
-- | |
$88.31 | |
$54.30 | |
-- | |
-- |
Cytokinetics Inc. (CYTK) Latest Closing Stock Price
Cytokinetics Inc. (CYTK) last closed at $63.95 as of 2026-10-21 23:31:00, unchanged from the previous close of $63.95.
During the latest regular trading session, CYTK traded between $3.05 and $110.25, with a volume of 801.67K shares. The closing price was near the middle and near the lower end of its 52-week range.
Cytokinetics Inc. (CYTK) 7-Day Stock Price Change
Over the past seven days, Cytokinetics Inc. (CYTK) moved from $62.79 to $62.90, representing a gain of 0.17% ($0.11).
The stock traded between $60.99 and $65.57 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 1.59 million shares, down versus the previous seven-day period, indicating lower trading activity.
CYTK 52-Week Price Position
Position in Range: 25.3%
CYTK is currently trading at $62.90, placing it 25.3% of the way from its 52-week low of $54.30 to its 52-week high of $88.31. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Cytokinetics Inc. (CYTK)?
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Cytokinetics Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 673 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Cytokinetics Inc. (CYTK) Stock on MEXC
Eligible investors can buy real shares of Cytokinetics Inc. (CYTK) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Cytokinetics Inc. (CYTK) stock price today?
2.Is CYTK stock going up or down today?
3.What is CYTK pre-market price?
4.What is CYTK after-hours price?
5.Is CYTK stock trading now?
6.Where does CYTK sit relative to its 52-week high and low?
7.What sector is Cytokinetics Inc. in?
8.What is Cytokinetics Inc.'s market capitalization and where is it listed?
9.How is CYTK valued in terms of P/E ratio and EPS?
10.Does Cytokinetics Inc. pay a dividend?
Explore More US Stocks
Search Stocks
CYTK Stock Calculator
Estimate the value between CYTK shares and USD.
CYTK Shares to USD
1.00 CYTK shares = 62.895 USD
Calculations are estimates based on the latest available price and are for reference only.


